Download or read book Generic Substitution and Prescription Drug Prices written by Alison Masson and published by . This book was released on 1985 with total page 366 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Generic Substitution and Prescription Drug Prices at the Retail Pharmacy written by Alison Masson and published by . This book was released on 1986 with total page 580 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Generic Substitution and Prescription Drug Prices written by Alison Masson and published by . This book was released on 1985 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Making Medicines Affordable written by National Academies of Sciences, Engineering, and Medicine and published by National Academies Press. This book was released on 2018-03-01 with total page 235 pages. Available in PDF, EPUB and Kindle. Book excerpt: Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Download or read book Generic Drug Laws written by Theodore Goldberg and published by . This book was released on 1986 with total page 584 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Effects of Using Generic Drugs on Medicare s Prescription Drug Spending written by Julie Ann Somers and published by DIANE Publishing. This book was released on 2010 with total page 36 pages. Available in PDF, EPUB and Kindle. Book excerpt: This is a print on demand edition of a hard to find publication. Contents:(1) Overview of the Medicare Prescription Drug Benefit Program: Design of the Medicare Prescription Drug Benefit; Distribution of Spending in Medicare Part D; The Role of Private Plans in Medicare Part D; (2) Generic Drugs in Medicare Part D: Generic Substitution; Therapeutic Substitution; Comparing Potential Savings from Generic and Therapeutic Substitution; (3) Implications of Future Developments: First-Time Generic Entry; New Brand-Name Drugs; Biologics. (4) Appendix: Description of Data Used in This Analysis. Charts and tables.
Download or read book How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry written by and published by U.S. Government Printing Office. This book was released on 1998 with total page 94 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Generic Substitute Drugs and Drug Prices written by Jerome Harleston and published by . This book was released on 2000 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Discusses whether a generic substitute drug written on a patient's prescription by a dispensing pharmacist must be available on the market, the rate of increase in prescription drug costs over the last several years, and the cost difference between brand name and generic substitute drugs.
Download or read book A Study on Generic Prescription Substitution Policy as a Cost Containment Approach for Michigan s Medicaid System written by Khandaker Nayeemul Islam and published by . This book was released on 2014 with total page 184 pages. Available in PDF, EPUB and Kindle. Book excerpt: Increasing health care costs have made management of Medicaid services to provide low income families through Medicaid programs critical in the recent times. The number of Medicaid beneficiaries in Michigan has increased over the years mainly due to the downsizing of auto sectors. Currently, states spend almost 16 percent of their budget for Medicaid, making it the second largest item in the budget for most. Prescription drugs are a significant part of Michigan's Medicaid costs. Higher costs caused a tremendous fiscal burden on Michigan in administering the program and providing prescription drugs for its patients. Michigan has implemented several strategies for Medicaid since 2001, which have brought modest results in terms of Medicaid cost containment. An AARP report found that 80 percent of drugs have therapeutic equivalents or generics available in the market while 20 percent of drugs have no generic substitutions. But depending on the nature of diseases generic substitutions for Medicaid prescription drugs could be much higher than 80 percent. Previous research suggests that Michigan has the potential to increase generic substitutions at least 10 percent to 15 percent. This study examined whether a generic substitution policy would be an efficient and effective cost containment strategy for Michigan Medicaid prescription drug programs. This research emphasized three questions: First, would a generic substitution policy be an efficient strategy in containing Medicaid prescription drug program costs for Michigan? Second, did any heavily used brand drugs exist which had generic equivalents allowing Michigan to safely reduce Medicaid prescription drug costs by implementing a generic substitution policy? Third, if the answer was yes to both questions, then approximately what amount could Michigan save per year by implementing the generic substitution policy? This research found that Michigan could save 170 million dollars by implementing a generic substitution policy in the prescription drugs program within the selected six year period between 1999 to 2010 . In 2010, Michigan could save more than 16 million dollars by only prescribing generics, instead of ten brand drugs. A total savings from generics could be approximately 40 million dollars if only generics were prescribed instead of brand drugs. The total amount could be much higher if the multi-vitamin category was included.
Download or read book Prescription Drug Pricing Background Discount Programs and Cost Lowering Strategies written by Elias B. Toft and published by Nova Snova. This book was released on 2020-03-13 with total page 248 pages. Available in PDF, EPUB and Kindle. Book excerpt: Chapter 1 examines the actions of drug companies in raising prescription drug prices in the United States, as well as the effects of these actions on the Federal and state budgets, and on American families. Chapter 2 addresses frequently asked questions about government and private-sector policies that affect drug prices and availability. Among the prescription drug topics covered are federally funded research and development, regulation of direct-to-consumer advertising, legal restrictions on reimportation, and federal price negotiation. The 340B Drug Pricing Program requires drug manufacturers to sell outpatient drugs at discounted prices to covered entitiesâeligible clinics, hospitals, and othersâin order to have their drugs covered by Medicaid. Covered entities are only allowed to provide 340B drugs to certain eligible patients. Chapter 3 reviews the Health Resources and Services Administration's (HRSA) oversight of the 340B Program to ensure compliance with program rules. In 2017, nearly 60% of U.S. adults aged 18â64 reported being prescribed medication in the past 12 months. Approximately 70% of prescription medications carry out-of-pocket costs. Strategies to reduce prescription drug costs at the individual level are discussed in chapters 4 and 5. Each year, Americans pay more for prescription drugs, and rising drug prices have a disproportionate impact on older Americans. Chapter 6 examines the history of rising drug prices for the brand-name drugs most commonly prescribed for seniors. Generic drugsâcopies of brand-name drugsâlead to significant cost savings. Before a generic drug can be marketed, FDA must approve the generic drug application. According to FDA, applications go through an average of three cycles of review before being approved, which may take years. Chapter 7 examines 1) the first review cycle approval rate of generic drug applications in recent years and factors that may have contributed to whether applications were approved; and 2) changes FDA has made to increase the first review cycle approval rate.
Download or read book Strategies Used by Adults to Reduce Their Prescription Drug Costs written by Robin A. Cohen and published by . This book was released on 2015 with total page 12 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Increasing Generic Drug Utilization written by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and published by . This book was released on 2005 with total page 102 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Generic Drugs Under Medicare written by United States Government Accountability Office and published by Createspace Independent Publishing Platform. This book was released on 2017-09-23 with total page 52 pages. Available in PDF, EPUB and Kindle. Book excerpt: Medicare is the largest public payer for prescription drugs, representing 29 percent of total retail prescription drug spending in 2014. Generic prescription drugs have been a source of cost savings for the U.S. health care system due to their lower costs relative to brand-name drugs. However, recent price increases of certain generics may limit cost savings. GAO was asked to examine price trends for generic drugs and the factors that affect prices. This report describes 1) how generic drug prices under Medicare Part D have changed over time; 2) the extent to which generic drugs under Medicare Part D experienced extraordinary price increases, the persistence of any increases, and their effect on benefit design; and 3) the factors stakeholders identified as contributing to price changes. GAO analyzed Medicare Part D claims data from the first quarter of 2010 through the second quarter of 2015, the most recent data available. Based on the data, GAO created price indexes to show price trends; determined the number of drugs that had an extraordinary price increase of 100 percent or more; and tracked whether the increased price remained at 100 percent or more for an additional year. GAO also interviewed drug manufacturers, Medicare Part D plan sponsors, pharmacy benefit managers, relevant trade associations,
Download or read book The Right Price written by Peter J. Neumann and published by Oxford University Press. This book was released on 2021-05-06 with total page 312 pages. Available in PDF, EPUB and Kindle. Book excerpt: The US prescription drug business is a $500 billion industry whose rising prices carry profound consequences for patients, caregivers, employers and taxpayers across the nation. In the United States, average prices of leading brand-name drugs are two to four times higher than prices charged in other wealthy countries, raising questions as to what Americans are getting for the extra expense. On the other hand, healthy industry returns have arguably fueled life-saving innovation. With the advent of ever more targeted and powerful treatments, including cell- and gene-based therapies with multi-million-dollar price tags, the need for sensible drug pricing policies will only intensify. The Right Price sheds light on the controversial topic of drug pricing by providing an accessible guide to pharmaceutical markets and analytic techniques used to measure the value of drug therapies. It illustrates the need for value-based pricing through real-life stories of patients and their experiences with the drug industry and explains why simple solutions like price controls and the importation of cheaper drugs from other countries are problematic. This volume describes how researchers and policy makers have pursued drug valuation efforts in the past, and lays out a series of recommendations, based on years of shared author experience serving on national drug policy platforms, for how to further improve pharmaceutical value assessment in the United States. With unique industry insights and clear narrative, The Right Price unveils why the pricing of drugs continues to be so challenging and how public and private officials can create more informed policies to achieve the right balance between drug pricing and value.
Download or read book Generic Vs Higher priced Name Brand Drugs written by and published by . This book was released on 1977 with total page 66 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Two Aspects of Drug Pricing written by Wisconsin. Legislature. Legislative Reference Bureau and published by . This book was released on 1976 with total page 24 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Regulating Pharmaceuticals In Europe Striving For Efficiency Equity And Quality written by Mossialos, Elias and published by McGraw-Hill Education (UK). This book was released on 2004-06-01 with total page 390 pages. Available in PDF, EPUB and Kindle. Book excerpt: "This thoughtful and comprehensive book represents the best work I have seen on the current situation concerning medication policies in the EU. It is not just that this is a very up-to-date compendium of facts and data across a wide variety of domains that impact on pharmaceutical regulation. The book is also strong on analysis of those facts as well." Jerry Avorn, Harvard Medical School. "This book offers a comprehensive examination of approaches to manage pharmaceutical expenditures in Europe. It is a must-read for those who seek to understand and navigate the changing regulatory environment for medicines in the European Union." Bernie O'Brien, McMaster University, Canada. The rising cost of pharmaceutical expenditures in many European countries is of concern to governments required to make effective use of health care budgets. Taking a broad perspective that encompasses institutional, political and supranational aspects of pharmaceutical regulation, this book examines approaches used to manage pharmaceutical expenditure across Europe and what impact these strategies have had on efficiency, quality, equity and cost of pharmaceutical care.Regulating Pharmaceuticals in Europe is an important book for students of health policy, regulation and management, and for health managers and policy makers. The editors: Elias Mossialos is Brian Abel-Smith Professor of Health Policy at the London School of Economics and Political Science and a Research Director of the European Observatory on Health Systems and Policies. Monique Mrazek is a Health Economist (Europe and Central Asia region) for the World Bank and formerly a Research Officer in Health Economics for the European Observatory on Health Systems and Policies. Tom Walley is Professor of Clinical Pharmacology at the University of Liverpool and Director of the UK National Health Technology Assessment Programme. Contributors:Julia Abelson, Christa Altenstetter, Vittorio Bertele’, Christine Bond, Marcel L. Bouvy, Colin Bradley, Steve Chapman, Anna Dixon, Michael Drummond, Pierre Durieux, Edzard Ernst, Armin Fidler, Eric Fortess, Richard Frank, Silvio Garattini, Leigh Hancher, Ebba Holme Hansen, Steve Hudson, Kees de Jonchere, Panos Kanavos, Sjoerd Kooiker, Jean-Marc Leder, Graham Lewis, Donald W. Light, Alistair McGuire, Elias Mossialos, Monique Mrazek, Maria Pia Orru', Govin Permanand, Guenka Petrova, Munir Pirmohamed, Dennis Ross-Degnan, Frans Rutten, Steven Soummerai, David Taylor, Sarah Thomson, Tom Walley.
